Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)
27.50
-0.90 (-3.17%)
Nov 20, 2026, 1:30 PM CST
TPEX:4111 Revenue
Chi Sheng Pharma & Biotech had revenue of 354.72M TWD in the quarter ending September 30, 2026, with 3.68% growth. This brings the company's total for the last twelve months to 1.43B, up 5.33% year-over-year. In the year 2025, Chi Sheng Pharma & Biotech had annual revenue of 1.38B with 18.11% growth. That makes Chi Sheng Pharma & Biotech the 28,999th largest company in the world by revenue and 1,395th in Taiwan.
Revenue (ttm)
1.43B
Revenue Growth
+5.33%
P/S Ratio
1.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.65B
Revenue by Geography
- Taiwan 1.15B 98.9%
- Others 12.33M 1.1%
Fiscal year ended Dec 31, 2024 See the full TPEX:4111 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.38B | 211.04M | 18.11% |
| Dec 31, 2024 | 1.17B | 104.57M | 9.86% |
| Dec 31, 2023 | 1.06B | -82.21M | -7.19% |
| Dec 31, 2022 | 1.14B | 120.78M | 11.81% |
| Dec 31, 2021 | 1.02B | 42.94M | 4.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BenQ Medical Technology | 5.40B |
| St.Shine Optical | 3.63B |
| Nang Kuang Pharmaceutical | 2.09B |
| ICARES Medicus | 1.31B |
| Concord Medical | 1.04B |
| Crystalvue Medical | 894.60M |
| Perfect Medical Industry | 886.30M |
| SciVision Biotech | 870.41M |